Maralixibat
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Familial Intrahepatic Cholestasis (PFIC)
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Trial Timeline
Jan 8, 2020 → Apr 23, 2025
NCT ID
NCT04185363About Maralixibat
Maralixibat is a phase 3 stage product being developed by Mirum Pharmaceuticals for Progressive Familial Intrahepatic Cholestasis (PFIC). The current trial status is completed. This product is registered under clinical trial identifier NCT04185363. Target conditions include Progressive Familial Intrahepatic Cholestasis (PFIC).
What happened to similar drugs?
2 of 20 similar drugs in Progressive Familial Intrahepatic Cholestasis (PFIC) were approved
Approved (2) Terminated (4) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04530994 | Pre-clinical | Completed |
| NCT07389031 | Phase 2 | Recruiting |
| NCT06553768 | Phase 3 | Recruiting |
| NCT04729751 | Phase 2 | Completed |
| NCT04524390 | Phase 2 | Completed |
| NCT04168385 | Phase 2 | Completed |
| NCT04185363 | Phase 3 | Completed |
| NCT03905330 | Phase 3 | Completed |
Competing Products
20 competing products in Progressive Familial Intrahepatic Cholestasis (PFIC)